🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
25/03/2021 31,25 33,56 30,36 33,43 +4,44% 10,24% 738.800
24/03/2021 34,98 34,98 31,87 32,01 -7,08% 8,89% 486.200
23/03/2021 35,41 35,41 33,98 34,45 -3,93% 4,04% 311.100
22/03/2021 37,09 37,65 35,41 35,86 -3,26% 6,04% 347.200
19/03/2021 35,29 37,18 34,97 37,07 +5,01% 6,26% 944.500
18/03/2021 35,86 37,86 35,17 35,30 -4,34% 7,50% 335.800
17/03/2021 34,44 37,37 34,13 36,90 +5,49% 9,42% 316.500
16/03/2021 35,03 36,00 34,01 34,98 -0,88% 5,68% 359.000
15/03/2021 36,20 36,95 34,96 35,29 -3,18% 5,51% 473.800
12/03/2021 38,51 39,19 35,43 36,45 -6,56% 9,76% 709.800
11/03/2021 35,95 39,10 34,70 39,01 +9,46% 12,24% 1.130.200
10/03/2021 33,15 35,93 32,66 35,64 +10,07% 9,86% 466.600
09/03/2021 32,34 33,48 31,70 32,38 +2,83% 5,50% 321.500
08/03/2021 33,92 33,95 30,81 31,49 -7,41% 9,26% 617.500
05/03/2021 33,79 34,59 31,70 34,01 +1,86% 8,55% 625.400
04/03/2021 34,15 35,97 33,00 33,39 -3,36% 8,70% 707.800
03/03/2021 36,19 36,28 34,09 34,55 -4,74% 6,05% 588.200
02/03/2021 36,65 36,89 35,19 36,27 -1,20% 4,65% 380.200
01/03/2021 35,59 36,87 35,52 36,71 +4,11% 3,79% 328.700
26/02/2021 34,26 35,59 33,68 35,26 +2,95% 5,58% 366.900
25/02/2021 35,77 36,21 33,44 34,25 -3,06% 7,74% 482.000
24/02/2021 33,13 35,77 32,47 35,33 +6,16% 9,96% 479.600
23/02/2021 31,43 35,00 30,85 33,28 +2,84% 13,20% 737.400
22/02/2021 31,39 33,04 30,85 32,36 +2,21% 6,98% 564.700
19/02/2021 32,06 33,31 31,41 31,66 -0,88% 5,93% 472.400
18/02/2021 34,00 34,00 31,12 31,94 -3,82% 8,47% 653.000
17/02/2021 33,62 34,16 32,11 33,21 -2,04% 6,10% 999.100
16/02/2021 36,44 37,00 33,75 33,90 -5,83% 8,92% 423.500
12/02/2021 37,10 37,22 34,98 36,00 -2,70% 6,04% 688.900
11/02/2021 38,69 38,69 36,76 37,00 -3,90% 4,99% 453.900